SARS-CoV-2 PCR and antibody testing for an entire rural community: methods and feasibility of high-throughput testing procedures.

COVID-19 COVID-19 diagnostic testing Feasability Studies Rural Population

Journal

Archives of public health = Archives belges de sante publique
ISSN: 0778-7367
Titre abrégé: Arch Public Health
Pays: England
ID NLM: 9208826

Informations de publication

Date de publication:
07 Jul 2021
Historique:
received: 20 07 2020
accepted: 21 06 2021
entrez: 8 7 2021
pubmed: 9 7 2021
medline: 9 7 2021
Statut: epublish

Résumé

Early in the pandemic, inadequate SARS-CoV-2 testing limited understanding of transmission. Chief among barriers to large-scale testing was unknown feasibility, particularly in non-urban areas. Our objective was to report methods of high-volume, comprehensive SARS-CoV-2 testing, offering one model to augment disease surveillance in a rural community. A community-university partnership created an operational site used to test most residents of Bolinas, California regardless of symptoms in 4 days (April 20th - April 23rd, 2020). Prior to testing, key preparatory elements included community mobilization, pre-registration, volunteer recruitment, and data management. On day of testing, participants were directed to a testing lane after site entry. An administrator viewed the lane-specific queue and pre-prepared test kits, linked to participants' records. Medical personnel performed sample collection, which included finger prick with blood collection to run laboratory-based antibody testing and respiratory specimen collection for polymerase chain reaction (PCR). Using this 4-lane model, 1,840 participants were tested in 4 days. A median of 57 participants (IQR 47-67) were tested hourly. The fewest participants were tested on day 1 (n = 338 participants), an intentionally lower volume day, increasing to n = 571 participants on day 4. The number of testing teams was also increased to two per lane to allow simultaneous testing of multiple participants on days 2-4. Consistent staffing on all days helped optimize proficiency, and strong community partnership was essential from planning through execution. High-volume ascertainment of SARS-CoV-2 prevalence by PCR and antibody testing was feasible when conducted in a community-led, drive-through model in a non-urban area.

Sections du résumé

BACKGROUND BACKGROUND
Early in the pandemic, inadequate SARS-CoV-2 testing limited understanding of transmission. Chief among barriers to large-scale testing was unknown feasibility, particularly in non-urban areas. Our objective was to report methods of high-volume, comprehensive SARS-CoV-2 testing, offering one model to augment disease surveillance in a rural community.
METHODS METHODS
A community-university partnership created an operational site used to test most residents of Bolinas, California regardless of symptoms in 4 days (April 20th - April 23rd, 2020). Prior to testing, key preparatory elements included community mobilization, pre-registration, volunteer recruitment, and data management. On day of testing, participants were directed to a testing lane after site entry. An administrator viewed the lane-specific queue and pre-prepared test kits, linked to participants' records. Medical personnel performed sample collection, which included finger prick with blood collection to run laboratory-based antibody testing and respiratory specimen collection for polymerase chain reaction (PCR).
RESULTS RESULTS
Using this 4-lane model, 1,840 participants were tested in 4 days. A median of 57 participants (IQR 47-67) were tested hourly. The fewest participants were tested on day 1 (n = 338 participants), an intentionally lower volume day, increasing to n = 571 participants on day 4. The number of testing teams was also increased to two per lane to allow simultaneous testing of multiple participants on days 2-4. Consistent staffing on all days helped optimize proficiency, and strong community partnership was essential from planning through execution.
CONCLUSIONS CONCLUSIONS
High-volume ascertainment of SARS-CoV-2 prevalence by PCR and antibody testing was feasible when conducted in a community-led, drive-through model in a non-urban area.

Identifiants

pubmed: 34233752
doi: 10.1186/s13690-021-00647-8
pii: 10.1186/s13690-021-00647-8
pmc: PMC8261397
doi:

Types de publication

Journal Article

Langues

eng

Pagination

125

Subventions

Organisme : NIAID NIH HHS
ID : K24 AI144048
Pays : United States
Organisme : Chan Zuckerberg Biohub Investigator Program
ID : Chan Zuckerberg Biohub Investigator Program
Organisme : Bolinas Community Land Trust
ID : Bolinas Community Land Trust
Organisme : National Institute of Allergy and Infectious Diseases
ID : 5T32AI007641-17

Commentaires et corrections

Type : UpdateOf

Références

Am J Infect Control. 2020 Jun;48(6):731-732
pubmed: 32305432
Emerg Infect Dis. 2020 Jul;26(7):
pubmed: 32364890
Open Forum Infect Dis. 2020 Oct 30;8(1):ofaa531
pubmed: 34109255
Science. 2020 Jun 5;368(6495):1060-1061
pubmed: 32414781
J Korean Med Sci. 2020 Mar 23;35(11):e123
pubmed: 32193904

Auteurs

Ayesha Appa (A)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA. Ayesha.appa@ucsf.edu.

Gabriel Chamie (G)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.

Aenor Sawyer (A)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.

Kimberly Baltzell (K)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.

Kathryn Dippell (K)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.

Salu Ribeiro (S)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.

Elias Duarte (E)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.

Joanna Vinden (J)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.

Cliahub Consortium (C)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
Chan Zuckerberg Biohub, San Francisco, USA.

Jonathan Kramer-Feldman (J)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.

Shahryar Rahdari (S)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.

Doug MacIntosh (D)

San Francisco State University, San Francisco, USA.

Katherine Nicholson (K)

San Francisco State University, San Francisco, USA.

Jonathan Im (J)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.

Diane Havlir (D)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.

Bryan Greenhouse (B)

University of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.

Classifications MeSH